论文部分内容阅读
目的:研究趋化因子受体CXCR1在乳腺癌组织中的表达特征,并探讨新辅助化疗前后其表达变化与化疗疗效的关系。方法:选取20例正常乳腺组织,20例乳腺纤维腺瘤,104例乳腺癌标本,免疫组化染色后统计每例标本CXCR1的阳性表达积分,分析不同乳腺疾病CXCR1的表达差异。统计新辅助化疗前后乳腺癌标本CXCR1的阳性表达积分的变化,分析其与化疗病理反应的关系。结果:CXCR1在正常乳腺组织、乳腺纤维腺瘤中低表达,在乳腺癌组织上高表达;其表达与患者的年龄、原发肿瘤的大小无关(P>0.05),与病理分期、癌细胞的分化程度、淋巴结转移个数、激素受体状态及Her2表达情况相关,P<0.05,有统计学意义。新辅助化疗后,癌组织中CXCR1的表达下降,下降幅度越大,其化疗疗效越好。结论:CXCR1的检测对于乳腺疾病的良恶性判断有指导意义,可辅助判断乳腺癌的恶性程度、侵袭性以及预后,CXCR1表达的下降与化疗疗效相关,抑制其表达可能可以提高化疗疗效。
OBJECTIVE: To study the expression of chemokine receptor CXCR1 in breast cancer and to investigate the relationship between CXCR1 expression and chemotherapy efficacy before and after neoadjuvant chemotherapy. Methods: 20 cases of normal breast tissue, 20 cases of breast fibroadenoma and 104 cases of breast cancer were selected. The expression of CXCR1 in each sample was analyzed by immunohistochemistry and the expression of CXCR1 in different breast diseases was analyzed. Statistics of neoadjuvant chemotherapy before and after breast cancer specimens CXCR1 positive expression changes, analysis of its relationship with the pathological response to chemotherapy. Results: The expression of CXCR1 was low in normal breast tissue and breast fibroadenoma and high in breast cancer tissues. The expression of CXCR1 was not associated with the age and the size of the primary tumor (P> 0.05) Differentiation, lymph node metastasis, hormone receptor status and Her2 expression, P <0.05, with statistical significance. After neoadjuvant chemotherapy, the expression of CXCR1 in cancerous tissues decreased, the greater the extent of the decrease was, the better the effect of chemotherapy was. Conclusion: The detection of CXCR1 is of guiding significance for the benign and malignant diagnosis of breast disease. It may be helpful to judge the malignancy, invasiveness and prognosis of breast cancer. The decrease of CXCR1 expression is associated with the curative effect of chemotherapy. Inhibition of CXCR1 expression may improve the curative effect of chemotherapy.